BIOGEN Celebrates FDA Approval of Lecanemab to Treat Early Alzheimer’s Disease
January 12, 2023
Trending News ☀️
Biogen Inc ($NASDAQ:BIIB) is a global biotechnology company based in Cambridge, Massachusetts that develops and manufactures innovative therapies for serious neurological and neurodegenerative diseases. The company is well known for its pioneering work in developing treatments for Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and lupus. Last week, the U.S. Food and Drug Administration (FDA) approved the drug lecanemab, which was developed by the Japanese company Eisai and submitted for a marketing authorization application to treat early Alzheimer’s disease at the European Medicines Agency. He also noted that the approval of lecanemab is a testament to Biogen’s commitment to creating innovative therapies for serious neurological and neurodegenerative diseases.
The approval of lecanemab is an important step forward in the fight against Alzheimer’s disease. Biogen has been a leader in researching and developing treatments for this debilitating condition and this new drug will help provide relief to many patients suffering from early Alzheimer’s. While there is still much work to be done to find a cure for Alzheimer’s, Biogen’s success with lecanemab is a major step in the right direction.
Price History
BIOGEN Inc. recently celebrated the U.S. Food and Drug Administration’s (FDA) approval of its drug, Lecanemab, to treat early Alzheimer’s disease. News coverage of the event has been mostly positive, as the drug is expected to offer a much-needed treatment option for people with early-stage Alzheimer’s. On Wednesday, BIOGEN INC stock opened at $281.8 and closed at $285.0, up by 1.3% from prior closing price of 281.5 in the same day, indicating a positive response from the market. Analysts believe that the approval of Lecanemab may lead to more positive news for BIOGEN INC in the future. This will provide an important treatment option for people with the condition and could have a positive impact on the quality of life for those affected by it. The FDA’s approval is also expected to open up opportunities for BIOGEN INC to further develop its research and development in the area of Alzheimer’s disease treatments.
In addition, it will likely create new revenue streams for the company. Overall, BIOGEN INC’s recent success with Lecanemab is a welcome development in the fight against early Alzheimer’s disease. The FDA’s approval will provide a much-needed treatment option for those suffering from the condition and may lead to further growth for BIOGEN INC in the future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Biogen Inc. More…
| Total Revenues | Net Income | Net Margin |
| 10.36k | 2.86k | 23.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Biogen Inc. More…
| Operations | Investing | Financing |
| 2.4k | 1.6k | -1.73k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Biogen Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 24.85k | 12.09k | 88.72 |
Key Ratios Snapshot
Some of the financial key ratios for Biogen Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -10.0% | -24.3% | 35.2% |
| FCF Margin | ROE | ROA |
| 21.0% | 18.5% | 9.2% |
VI Analysis
BIOGEN INC is a medium risk investment according to VI Risk Rating. This rating is based on the company’s fundamentals and its long-term potential. The VI App has detected two risk warnings in the income sheet and balance sheet, which are only visible to registered users. These risk warnings are indicators of potential risks that investors should be aware of before committing to an investment. The VI App simplifies the process of analyzing a company’s fundamentals by providing a comprehensive overview of the company’s financial and business aspects. It provides an overview of the company’s financial data, including income statements, balance sheets, and cash flow statements. It also provides analysis of the company’s market position, products, management team, and competitors. The VI App is designed to help investors quickly identify potential risks of investing in a company. It provides detailed analysis of a company’s financial and business aspects, enabling investors to make informed decisions on whether to invest in the company or not. By using the VI App, investors can easily identify potential risks and make informed decisions about their investments. More…
VI Peers
In the biotechnology industry, Biogen Inc is up against some stiff competition from the likes of Eli Lilly and Co, Gilead Sciences Inc, and Intra-Cellular Therapies Inc. All three companies are leaders in the development of innovative treatments and therapies for a variety of diseases and disorders. Biogen Inc has developed a reputation for being a cutting-edge company that is constantly striving to bring new and improved treatments to market. This commitment to innovation has allowed Biogen Inc to maintain a strong position in the industry, despite the challenges posed by its competitors.
– Eli Lilly and Co ($NYSE:LLY)
Eli Lilly and Co is a global pharmaceutical company that develops and markets prescription medicines and vaccines for various medical conditions. The company’s market cap as of 2022 is 316.18B. Its return on equity (ROE) is 45.88%.
Eli Lilly and Co was founded in 1876 and is headquartered in Indianapolis, Indiana, United States. The company operates in more than 140 countries worldwide. Some of its products include treatments for diabetes, cancer, Alzheimer’s disease, and psychiatric disorders.
– Gilead Sciences Inc ($NASDAQ:GILD)
Gilead Sciences Inc is a research-based biopharmaceutical company that discovers, develops and commercialises innovative therapeutics. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead Sciences Inc has a market cap of 83.2B as of 2022 and a Return on Equity of 24.03%. The company’s products include antiviral therapies, treatments for cancer and inflammatory diseases.
– Intra-Cellular Therapies Inc ($NASDAQ:ITCI)
Intra-Cellular Therapies Inc is a clinical stage biopharmaceutical company that focuses on the development of drugs for the treatment of neuropsychiatric disorders. The company’s market cap as of 2022 was 4.47B, and its ROE was -42.76%. The company’s products are in various stages of development, and include candidates for the treatment of schizophrenia, bipolar disorder, and major depressive disorder.
Summary
Investors are optimistic about BIOGEN INC following the recent U.S. Food and Drug Administration (FDA) approval of the company’s lecanemab drug to treat early-onset Alzheimer’s disease. The approval has generated positive news coverage and has the potential to significantly boost BIOGEN’s sales and earnings in the coming months and years. Analysts have revised their price targets for the company in light of the news, with some predicting strong gains in share price in the near-term. With a strong pipeline of other drugs in development and an expanding presence in the Alzheimer’s space, BIOGEN is well-positioned for future growth.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
